<DOC>
	<DOCNO>NCT02341508</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability Lpathomab healthy volunteer . Additional endpoint include characterization pharmacokinetic ( PK ) , pharmacodynamic ( PD ) , immunogenicity profile single IV dose Lpathomab healthy volunteer .</brief_summary>
	<brief_title>A Phase 1a , Double-Blind , Placebo-Controlled , Single Ascending Dose Study Evaluate Lpathomab Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Key Healthy male female subject ≥ 18 year old 50 145 kg Laboratory value ECG Screening period within normal range evaluate clinically significant ( NCS ) Female subject must childbearing potential use doublebarrier method contraception Male subject must use doublebarrier contraception study period Subject able read , understand , sign inform consent form ( ICF ) HIPAA release Key Subjects diabetes mellitus ( glycated hemoglobin [ HbA1c ] ≥6.5 % ) prediabetes mellitus ( HbA1c 5.7 6.4 % ) . Male subject correct QT interval ( QTc ) &gt; 450 msec QRS interval &gt; 120 msec female subject QTc &gt; 470 QRS interval &gt; 120 msec . Subject 's blood pressure ( BP ) screen period exceed 140/90 mm Hg Subject positive HIV , hep B and/or hep C screening Subject significant psychiatric comorbidity include limited major depressionsevere , bipolar disorder schizophrenia spectrum disorder , history suicide attempt , active suicidal ideation 6 month prior screen . Subject significant advanced systemic illness , unstable severe medical condition ( ) end stage disease could put risk study , interfere outcome measure , affect compliance protocol procedures requirement . Subject history cancer stability/remission le 5 year , exception nonmetastatic basal and/or squamous cell carcinoma skin cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>